Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases [3] - The company is based in Waltham, MA and Boulder, CO [3] Key Developments - Andrew Robbins, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - A live webcast of the presentation will be available on the Investors & Media page of Cogent's website, with a replay accessible for 30 days post-event [2] Clinical Programs - The most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) [3] - The company is also conducting a Phase 1 study of a novel internally discovered FGFR2/3 inhibitor [3] - Cogent is developing a portfolio of targeted therapies aimed at mutations in ErbB2, PI3Kα, KRAS, and JAK2 [3]